about
Antiplatelet agents for chronic kidney diseaseAntiplatelet agents for chronic kidney diseaseAntiplatelet agents for chronic kidney diseaseSaxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes.Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.
P2860
Q24197614-E27D4BD1-92C8-4600-A618-B8961DEF9369Q24200752-639A4256-F7A3-4E9C-A32F-A1D022947CD0Q24234115-E4B57DB6-D8FC-4908-B08E-E744CBF5B478Q37982112-E30FEDB3-E538-4BB2-976F-C57BE955F0E2Q38086611-C71DE285-CB06-4119-BC86-7C42634B5610Q38261573-F31B4828-5A3F-4944-BF39-6B3D637650FBQ38989517-75416081-20B2-431E-9B4F-B93A8B6F7F6B
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Medications in the kidney.
@en
Medications in the kidney.
@nl
type
label
Medications in the kidney.
@en
Medications in the kidney.
@nl
prefLabel
Medications in the kidney.
@en
Medications in the kidney.
@nl
P2860
P1433
P1476
Medications in the kidney.
@en
P2093
A J Scheen
P2860
P356
10.1179/ACB.2008.63.2.003
P577
2008-03-01T00:00:00Z